PharmaTimes2h
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
PharmaTimes2h
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for ...
PharmaTimes21h
AstraZeneca receives positive recommendations for lung cancer treatments
AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...
PharmaTimes23h
Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease
This initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU) with over EUR 38 million, aims to ...